Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Kaufman HL, Seebach F, Lowy I, Yoo SY, Mathias M, Fenech K, Han H, Fury MG, Rischin D. Gross ND, et al. Among authors: choe jh. N Engl J Med. 2022 Oct 27;387(17):1557-1568. doi: 10.1056/NEJMoa2209813. Epub 2022 Sep 12. N Engl J Med. 2022. PMID: 36094839 Free PMC article. Clinical Trial.
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Yoo SY, Mathias M, Han H, Seebach F, Lowy I, Fury MG, Rischin D. Gross ND, et al. Among authors: choe jh. Lancet Oncol. 2023 Nov;24(11):1196-1205. doi: 10.1016/S1470-2045(23)00459-X. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875144 Clinical Trial.
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Lim EA, Bendell JC, Falchook GS, Bauer TM, Drake CG, Choe JH, George DJ, Karlix JL, Ulahannan S, Sachsenmeier KF, Russell DL, Moorthy G, Sidders BS, Pilling EA, Chen H, Hattersley MM, Das M, Kumar R, Pouliot GP, Patel MR. Lim EA, et al. Among authors: choe jh. Clin Cancer Res. 2022 Nov 14;28(22):4871-4884. doi: 10.1158/1078-0432.CCR-22-0612. Clin Cancer Res. 2022. PMID: 36044531 Free PMC article. Clinical Trial.
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. Hong DS, et al. Among authors: choe jm, choe jh. Invest New Drugs. 2013 Aug;31(4):918-26. doi: 10.1007/s10637-012-9898-3. Epub 2012 Nov 20. Invest New Drugs. 2013. PMID: 23179336 Free PMC article. Clinical Trial.
Medication persistence and its impact on type 2 diabetes.
Choe JH, Xuan S, Goldenberg A, Matian J, McCombs J, Kim RE. Choe JH, et al. Am J Manag Care. 2024 Apr 1;30(4):e124-e134. doi: 10.37765/ajmc.2024.89534. Am J Manag Care. 2024. PMID: 38603538 Free article.
245 results